The mechanisms for the pharmacological action of CHM for AKI include an antioxidant activity by scavenging reactive oxygen species (ROS) and improving renal levels of superoxide dismutase (SOD) [9, 10] and an anti-inflammatory activity by reducing interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-α) levels [11]. Here, TNF is linked to acute kidney injury.